Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • TScan Therapeutics

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Lilly’s Omvoh shows improved outcomes in ulcerative colitis

    The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Abivax shares positive late-stage results for obefazimod in ulcerative colitis

    Inflammatory bowel disease affects nearly one in every 100 people in the US

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    - PMLiVE

    Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    - PMLiVE

    J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    - PMLiVE

    Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

    More than 2.5 million people in Europe are affected by the inflammatory bowel disease

    - PMLiVE

    Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

    More than 2.5 million people in Europe are living with the inflammatory bowel disease

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    - PMLiVE

    Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

    An estimated three million people in the US are affected by inflammatory bowel disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links